期刊文献+

血管内超声虚拟组织学成像评价氟伐他汀对冠状动脉斑块退缩及其成分的影响 被引量:1

Effect of fluvastatin on recession of coronary atherosclerotic plaque and its composition:Evaluation by intravascular ultrasound virtual histology
下载PDF
导出
摘要 背景:近年来有很多关于抗动脉粥样硬化的大规模临床研究,其中应用血管内超声评价他汀类药物疗效的临床研究最值得关注,至于冠状动脉斑块成分的变化未见报道。目的:应用血管内超声传统灰阶成像及虚拟组织学成像,评价氟发他汀对冠状动脉斑块退缩及其成分的影响。方法:纳入22例临床初诊为冠状动脉粥样硬化性心脏病的患者接受冠状动脉造影检查,至少有1支主要冠脉分支经定量冠状动脉造影目测狭窄程度为20%~50%,将其选做目标血管。造影后对目标血管行血管内超声检查,记录灰阶及虚拟组织学图像。所有患者在检查结束后予以80mg氟伐他汀治疗12个月。比较80mg氟伐他汀调脂治疗前后低密度脂蛋白胆固醇以及总胆固醇浓度变化,通过血管内超声灰阶成像及虚拟组织学成像分析斑块体积及成分变化。结果与结论:冠状动脉轻度病变患者通过80mg氟伐他汀治疗12个月后,可以显著增加钙化成分比例,同时显著减少坏死核心成分比例以及纤维脂质成分比例,起到积极稳定斑块的作用。但是患者在治疗后斑块体积增加而管腔体积减小,并没有明显逆转斑块进展。 BACKGROUND:Recent years,antiatherosclerotic clinical studies have been conducted,and statins effect has been evaluated by intravascular unltrasound (IVUS). Very little is known about changed in coronary atherosclerotic plaque. OBJECTIVE:To evaluate the effects of medium dosage fluvastatin on coronary atherosclerotic plaque and its composition by gray-scale IVUS and virtual histology-IVUS analysis. METHODS:A total of 22 patients who had been preliminarily clinically diagnosed as coronary heart disease were performed coronary angiography. These selected patients should have at least one major coronary branch whose stenosis extent was 20%-50% by coronary angiography examination with eye measurement. The gray scale IVUS and virtual histology IVUS after selecting the stenosis arteria coronary as target vessel were recorded and the target blood vessel was examined by IVUS. All selected patients were treated with 80 mg fluvastatin for 12 months after the examination. The low density lipoprotein cholesterol and total cholesterol levels of patients before and after the treatment were compared. Meanwhile the plaque volume and composition variation using IVUS were also analyzed. RESULTS AND CONCLUSION:After 12 months of 80 mg fluvastatin,the proportion of dense calcium was significantly increased,and the proportion of necrotic core was decreased,which stabilized plaque. However,the volume of plaque was increased but lumens decreased,not reversing plaque progression.
出处 《中国组织工程研究与临床康复》 CAS CSCD 北大核心 2010年第52期9786-9789,共4页 Journal of Clinical Rehabilitative Tissue Engineering Research
  • 相关文献

参考文献2

二级参考文献23

  • 1Steven E. Nissen,Stephen J. Nicholls,Ilks Sipahi,Peter Libby,Joel S. Raichlen,Christie M. Ballantyne,Jean Davignon,Raimund Erbel,Jean Charles Fruchart,Jean-Claude Tardif,Paul Schoenhagen,Tim Crowe,Valerie Cain,Kathy Wolski,Marlene Coormastic,E. Murat Tuzcu,仝其广(译),王淑敏(译),胡大一(校).极高强度他汀治疗对冠状动脉粥样硬化消退的影响——ASTEROID试验[J].美国医学会杂志(中文版),2006,25(4):215-223. 被引量:346
  • 2Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
  • 3LaRosa JC, Grundy SM, Waters DD, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
  • 4Pedersen TR, Faergeman O, Kastelein J J, et al; Incremental Decrease in End Points Through Aggressive Lipid Lowedng (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study:a randomized controlled trial. JAMA. 2005;294:2437-2445.
  • 5Grundy SM, Cleeman JI, Merz CN, et al; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel Ⅲ Guidelines. J Am Coll Cardiol. 2004;44:720-732.
  • 6Blankenhom DH, Azen SP, Kramsch DM, et al;MARS Research Group. Coronary angiographic changes with Iovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med.1993;119:969-976.
  • 7Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed be serial quantitaUve arteriography: the Canadian Coronary Atherosclerosis Intervention Trial(CCAIT). Circulation. 1994;89:959-968.
  • 8Jukema JW, Bruschke AV, van Boven A J, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-2540.
  • 9Pitt B, Mancini GB, Ellis SG, Rosrnan HS, Park J-S,McGovem ME. Pravastatin limitaUon of atherosclerosis in the coronary arteries (PLAC Ⅰ): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol. 1995;26:1133-1139.
  • 10Brown G, Albers J J, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipidlowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.

共引文献358

同被引文献6

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部